Trial Profile
An observational, retrospective, multicenter study to assess the efficacy of fingolimod in clinical practice in patients with relapsing-remitting multiple sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms NEXT
- 27 Jun 2017 Results (n=988) of a pooled analysis of two observational retrospective studies MS SECOND LINE GATE and MS NEXT assessing basal characteristics and effectiveness of fingolimod, presented at the 3rd Congress of the European Academy of Neurology
- 28 Apr 2017 Results (n=988) of a pooled analysis of two observational retrospective studies (MS SECOND LINE GATE and MS NEXT) assessing safety and tolerability of fingolimod in Spanish clinical practice, presented at the 69th Annual Meeting of the American Academy of Neurology
- 28 Apr 2017 Results of pooled analysis of two observational retrospective studies (MS SECOND LINE GATE and MS NEXT) presented at the 69th Annual Meeting of the American Academy of Neurology